Bert Vogelstein
Overview
Explore the profile of Bert Vogelstein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
309
Citations
68943
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tie J, Wang Y, Lo S, Lahouel K, Cohen J, Wong R, et al.
Nat Med
. 2025 Mar;
PMID: 40055522
Early data from the DYNAMIC study of circulating tumor DNA (ctDNA)-guided adjuvant chemotherapy (ACT) versus standard approach met its primary outcome demonstrating reduced ACT use without compromising 2-year recurrence-free survival...
2.
Cook A, Sur S, Dobbyn L, Watson E, Cohen J, Ptak B, et al.
Elife
. 2025 Feb;
13.
PMID: 39960487
Despite exciting developments in cancer immunotherapy, its broad application is limited by the paucity of targetable antigens on the tumor cell surface. As an intrinsic cellular pathway, nonsense-mediated decay (NMD)...
3.
Pearlman A, Wang Y, Kalluri A, Parker M, Cohen J, Dudley J, et al.
medRxiv
. 2024 Dec;
PMID: 39677487
Statement Of Significance: There is a paucity of technologies beyond surgical biopsy that can accurately diagnose central nervous system neoplasms. We developed a novel, sensitive and highly specific assay that...
4.
Yurgelun M, Rhees J, Papadopoulos N, Vogelstein B, Boland C
Gastroenterology
. 2024 Jul;
168(2):195-199.
PMID: 39038760
No abstract available.
5.
Mog B, Marcou N, DiNapoli S, Pearlman A, Nichakawade T, Hwang M, et al.
Sci Transl Med
. 2024 Jul;
16(755):eadg7123.
PMID: 38985855
Two types of engineered T cells have been successfully used to treat patients with cancer, one with an antigen recognition domain derived from antibodies [chimeric antigen receptors (CARs)] and the...
6.
Nichakawade T, Ge J, Mog B, Lee B, Pearlman A, Hwang M, et al.
Nature
. 2024 Mar;
628(8007):416-423.
PMID: 38538786
Antibody and chimeric antigen receptor (CAR) T cell-mediated targeted therapies have improved survival in patients with solid and haematologic malignancies. Adults with T cell leukaemias and lymphomas, collectively called T...
7.
Douville C, Lahouel K, Kuo A, Grant H, Avigdor B, Curtis S, et al.
Sci Transl Med
. 2024 Jan;
16(731):eadi3883.
PMID: 38266106
We previously described an approach called RealSeqS to evaluate aneuploidy in plasma cell-free DNA through the amplification of ~350,000 repeated elements with a single primer. We hypothesized that an unbiased...
8.
Cook A, Sur S, Dobbyn L, Watson E, Cohen J, Ptak B, et al.
bioRxiv
. 2024 Jan;
PMID: 38234817
One Sentence Summary: Disruption of the nonsense-mediated decay pathway with a newly developed SMG1 inhibitor with activity increases the expression of T-cell targetable cancer neoantigens resulting from truncating mutations.
9.
Chu L, Ahmed T, Blanco A, Javed A, Weisberg E, Kawamoto S, et al.
J Comput Assist Tomogr
. 2023 Nov;
47(6):845-849.
PMID: 37948357
Background: Existing (artificial intelligence [AI]) tools in radiology are modeled without necessarily considering the expectations and experience of the end user-the radiologist. The literature is scarce on the tangible parameters...
10.
Chan T, Hermeking H, Lengauer C, Kinzler K, Vogelstein B
Nature
. 2023 Aug;
621(7977):E28-E29.
PMID: 37626188
No abstract available.